Quoin Pharmaceuticals' QRX003 Receives Orphan Drug and Fast Track Designations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Globenewswire
Quoin Pharmaceuticals Ltd's stock rose by 5.22% as it crossed above the 5-day SMA, reflecting positive market sentiment.
The company announced that its investigational product QRX003 has received Orphan Drug Designation and Fast Track Certification from the FDA, indicating significant progress in its development for treating Netherton Syndrome. Additionally, the FDA has conditionally approved the brand name QYLEKI for QRX003, marking a crucial milestone in the commercialization process. The pivotal Phase 3 trials are expected to begin in the second half of 2026, with a potential New Drug Application filing anticipated in 2027.
This news positions Quoin Pharmaceuticals favorably in the biopharmaceutical sector, as the designations may expedite the development and market introduction of QYLEKI, potentially leading to new treatment options for patients with rare diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNRX
Wall Street analysts forecast QNRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.600
Low
70.00
Averages
70.00
High
70.00
Current: 4.600
Low
70.00
Averages
70.00
High
70.00
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
Quoin Pharmaceuticals' QYLEKI Receives Conditional FDA Approval
- Conditional FDA Approval: Quoin Pharmaceuticals announced that its investigational product QRX003, aimed at treating Netherton Syndrome, has received conditional approval for the brand name QYLEKI from the FDA, marking a significant milestone in the company's drug development journey.
- New Drug Application Plans: The company intends to include a proprietary name review request for QYLEKI in the New Drug Application for QRX003, which is expected to pave the way for future market introduction.
- Clinical Trial Progress: The QYLEKI lotion is currently being evaluated in Phase 2 whole-body clinical trials for patients with Netherton Syndrome, demonstrating the company's ongoing commitment to addressing rare diseases.
- Future Research Plans: The pivotal Phase 3 study is anticipated to begin in the second half of 2026, with a potential NDA filing in 2027, further advancing the company's strategic positioning in the biopharmaceutical sector.
See More
QRX003 Receives Orphan Drug and Fast Track Designations
- Orphan Drug Designation: QRX003 has received Orphan Drug Designation in the U.S., EU, and Japan, highlighting its significance in the rare disease treatment landscape and potentially providing a competitive market advantage for Quoin Pharmaceuticals.
- Fast Track Certification: The FDA has granted QRX003 Fast Track and Rare Pediatric Disease Designations, indicating an expedited development process, with pivotal Phase 3 trials expected to commence in the second half of 2026.
- Brand Name Approval: The FDA's conditional acceptance of QYLEKI as the brand name for QRX003 marks a significant milestone in the commercialization process, and if approved, it will be the first treatment for Netherton Syndrome.
- Positive Clinical Update: A positive update from the ongoing Pediatric Compassionate Use Program released on June 16 further enhances QRX003's market outlook, with a potential New Drug Application (NDA) filing anticipated in 2027, offering new treatment options for patients.
See More
Quoin Establishes Subsidiary in Japan to Advance QRX003 Commercialization
- Subsidiary Establishment: Quoin has established a wholly-owned subsidiary in Japan to directly commercialize QRX003 for treating Netherton Syndrome, marking a strategic advancement in one of its three core markets.
- Orphan Drug Designation: QRX003 recently received Orphan Drug Designation from Japan's MHLW, providing crucial policy support for its commercialization in Japan and enhancing market access potential.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially becoming the first approved treatment for this condition if successful.
- Global Market Strategy: In addition to Japan, Quoin has established nine commercial partnerships across 61 countries, which, combined with its core market strategy, could facilitate almost global availability of QRX003 if approved, further solidifying the company's market position.
See More
Quoin Pharmaceuticals Receives Orphan Drug Designation in Japan for QRX003
- Orphan Drug Designation: Quoin Pharmaceuticals announced that its drug QRX003 for treating Netherton Syndrome has received orphan drug designation from Japan's MHLW, providing up to 10 years of market exclusivity, significantly enhancing its competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing a phase 2 whole-body trial for Netherton syndrome patients, with a phase 3 study expected to begin in the second half of 2026 and an NDA filing anticipated in 2027, marking a crucial milestone in the drug development process.
- International Regulatory Recognition: In addition to Japan's orphan drug designation, QRX003 has also received pediatric rare disease designation and fast track designation from the U.S. FDA, as well as orphan drug designation from the EMA, indicating broad recognition and potential market opportunities globally.
- Strategic Market Positioning: Quoin CEO Michael Myers stated that Japan is a strategically important market for QRX003, and the company plans to self-commercialize the drug and other pipeline products upon approval, further strengthening its position in the global biopharmaceutical market.
See More
Japan Grants Orphan Drug Designation to QRX003
- Orphan Drug Designation: Japan's Ministry of Health grants Orphan Drug Designation to QRX003, allowing for up to 10 years of market exclusivity upon approval, significantly enhancing Quoin's competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially leading to an NDA filing in 2027 if successful.
- Strategic Market Importance: Japan is identified as a strategic market for QRX003, with Quoin planning to self-commercialize the drug and other pipeline products post-approval, which will aid in expanding the company's market share globally.
- Global Regulatory Recognition: QRX003 has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and the European Medicines Agency, further solidifying its potential as an effective treatment for Netherton Syndrome and addressing urgent medical needs for patients.
See More
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
Quoin Pharmaceuticals' QYLEKI Receives Conditional FDA Approval
- Conditional FDA Approval: Quoin Pharmaceuticals announced that its investigational product QRX003, aimed at treating Netherton Syndrome, has received conditional approval for the brand name QYLEKI from the FDA, marking a significant milestone in the company's drug development journey.
- New Drug Application Plans: The company intends to include a proprietary name review request for QYLEKI in the New Drug Application for QRX003, which is expected to pave the way for future market introduction.
- Clinical Trial Progress: The QYLEKI lotion is currently being evaluated in Phase 2 whole-body clinical trials for patients with Netherton Syndrome, demonstrating the company's ongoing commitment to addressing rare diseases.
- Future Research Plans: The pivotal Phase 3 study is anticipated to begin in the second half of 2026, with a potential NDA filing in 2027, further advancing the company's strategic positioning in the biopharmaceutical sector.
See More
QRX003 Receives Orphan Drug and Fast Track Designations
- Orphan Drug Designation: QRX003 has received Orphan Drug Designation in the U.S., EU, and Japan, highlighting its significance in the rare disease treatment landscape and potentially providing a competitive market advantage for Quoin Pharmaceuticals.
- Fast Track Certification: The FDA has granted QRX003 Fast Track and Rare Pediatric Disease Designations, indicating an expedited development process, with pivotal Phase 3 trials expected to commence in the second half of 2026.
- Brand Name Approval: The FDA's conditional acceptance of QYLEKI as the brand name for QRX003 marks a significant milestone in the commercialization process, and if approved, it will be the first treatment for Netherton Syndrome.
- Positive Clinical Update: A positive update from the ongoing Pediatric Compassionate Use Program released on June 16 further enhances QRX003's market outlook, with a potential New Drug Application (NDA) filing anticipated in 2027, offering new treatment options for patients.
See More
Quoin Establishes Subsidiary in Japan to Advance QRX003 Commercialization
- Subsidiary Establishment: Quoin has established a wholly-owned subsidiary in Japan to directly commercialize QRX003 for treating Netherton Syndrome, marking a strategic advancement in one of its three core markets.
- Orphan Drug Designation: QRX003 recently received Orphan Drug Designation from Japan's MHLW, providing crucial policy support for its commercialization in Japan and enhancing market access potential.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially becoming the first approved treatment for this condition if successful.
- Global Market Strategy: In addition to Japan, Quoin has established nine commercial partnerships across 61 countries, which, combined with its core market strategy, could facilitate almost global availability of QRX003 if approved, further solidifying the company's market position.
See More
Quoin Pharmaceuticals Receives Orphan Drug Designation in Japan for QRX003
- Orphan Drug Designation: Quoin Pharmaceuticals announced that its drug QRX003 for treating Netherton Syndrome has received orphan drug designation from Japan's MHLW, providing up to 10 years of market exclusivity, significantly enhancing its competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing a phase 2 whole-body trial for Netherton syndrome patients, with a phase 3 study expected to begin in the second half of 2026 and an NDA filing anticipated in 2027, marking a crucial milestone in the drug development process.
- International Regulatory Recognition: In addition to Japan's orphan drug designation, QRX003 has also received pediatric rare disease designation and fast track designation from the U.S. FDA, as well as orphan drug designation from the EMA, indicating broad recognition and potential market opportunities globally.
- Strategic Market Positioning: Quoin CEO Michael Myers stated that Japan is a strategically important market for QRX003, and the company plans to self-commercialize the drug and other pipeline products upon approval, further strengthening its position in the global biopharmaceutical market.
See More
Japan Grants Orphan Drug Designation to QRX003
- Orphan Drug Designation: Japan's Ministry of Health grants Orphan Drug Designation to QRX003, allowing for up to 10 years of market exclusivity upon approval, significantly enhancing Quoin's competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially leading to an NDA filing in 2027 if successful.
- Strategic Market Importance: Japan is identified as a strategic market for QRX003, with Quoin planning to self-commercialize the drug and other pipeline products post-approval, which will aid in expanding the company's market share globally.
- Global Regulatory Recognition: QRX003 has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and the European Medicines Agency, further solidifying its potential as an effective treatment for Netherton Syndrome and addressing urgent medical needs for patients.
See More
